Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer

被引:106
作者
Tanaka, M
Hashiguchi, Y
Ueno, H
Hase, K
Mochizuki, H
机构
[1] Self Def Forces Cent Hosp, Dept Surg, Setagaya Ku, Tokyo 1548532, Japan
[2] Natl Def Med Coll, Dept Surg 1, Tokorozawa, Saitama 359, Japan
关键词
colon cancer; T3; stage II; tumor budding; chemotherapy; recurrence; survival;
D O I
10.1007/s10350-004-7280-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: The aim of this study was to identify indicators that can predict patients at high risk of tumor recurrence in Stage II, T3 colon cancer. Methods: A total of 138 patients classified as Stage II, T3 underwent curative resection of colon cancer between 1981 and 1993. Clinical variables included age, gender, bowel obstruction, tumor location, and emergency presentation. For each colon tumor specimen, the following histopathological variables were assessed: maximum tumor diameter (<5 vs. >= 5 cm), depth, tumor grade (well and moderate vs. other), lymphatic and venous invasion (absent vs. present), perineural invasion, tumor necrosis, and tumor margin (expanding vs. infiltrating). We also categorized tumor budding, defined as a single cancer cell or small clusters of undifferentiated cancer cells in the invasive frontal lesion, into two categories: none or minimal (BD-1), and moderate or severe (BD-2). Univariate analysis for factors regarding recurrence and disease-specific survival were performed with the logistic regression model and the log-rank test. Results: Among the factors analyzed, tumor budding was the only factor that was significantly associated with recurrence and survival. The numbers of patients with BD-1 and BD-2 tumors were 111 and 27, respectively. Forty-eight percent of BD-2 tumor patients developed recurrence, compared with 4.5 percent of BD-1 tumor patients (P<0.0001). The cumulative disease-specific survival rates at five years for patients with BD-1 and BD-2 tumors were 98 and 74 percent, respectively (P<0.0001). Conclusion: The presence of moderate or severe budding at the invasive margin in Stage II, T3 colon cancer indicated a high risk of tumor recurrence after curative surgery, providing useful information for the decision regarding postoperative adjuvant chemotherapy.
引用
收藏
页码:1054 / 1059
页数:6
相关论文
共 36 条
[1]  
[Anonymous], HISTOLOGICAL CLASSIF
[3]   p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy [J].
Buglioni, S ;
D'Agnano, I ;
Vasselli, S ;
Donnorso, RP ;
D'Angelo, C ;
Brenna, A ;
Benevelo, M ;
Cosimelli, M ;
Zupi, G ;
Mottolese, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 116 (03) :360-368
[4]   Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence [J].
Burdy, G ;
Panis, Y ;
Alves, A ;
Nemeth, J ;
Lavergne-Slove, A ;
Valleur, P .
DISEASES OF THE COLON & RECTUM, 2001, 44 (11) :1682-1688
[5]  
Cascinu S, 2000, CLIN CANCER RES, V6, P2803
[6]  
Cascinu S, 1998, CANCER-AM CANCER SOC, V83, P1081, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1081::AID-CNCR5>3.3.CO
[7]  
2-N
[8]  
Clarke G, 1999, EUR J HISTOCHEM, V43, P311
[9]   Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [J].
Erlichman, C ;
O'Connell, M ;
Kahn, M ;
Marsoni, S ;
Torri, V ;
Tardio, B ;
Zaniboni, A ;
Pancera, G ;
Martignoni, G ;
Labianca, R ;
Barni, A ;
Seitz, JF ;
Milan, C ;
Bedenne, L ;
Giovannini, M ;
Letreut, YP ;
Skillings, J ;
Shepard, L ;
Zee, B ;
Petrioli, R ;
Francini, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1356-1363
[10]   PATHOLOGICAL FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST PROJECT (PROTOCOL NO 4) .4. SIGNIFICANCE OF TUMOR NECROSIS [J].
FISHER, ER ;
PALEKAR, AS ;
GREGORIO, RM ;
REDMOND, C ;
FISHER, B .
HUMAN PATHOLOGY, 1978, 9 (05) :523-530